RevOpsis Therapeutics
Harnessing a new era of multispecific biologics to discover and develop breakthrough treatments
Harnessing a new era of multispecific biologics to discover and develop breakthrough treatments
RevOpsis Therapeutics is a next-generation biopharmaceutical company pioneering a new era in multispecific antibody discovery and development. Their proprietary Rev-Mod Platform utilizes a modular plug-and-play system with a library of ~30 billion fully human and fully compatible antibody components, simplifying drug discovery. Their lead asset, RO-104, is a first-in-class trispecific biologic targeting three clinically validated pathways implicated in retinal vascular diseases. The company recently secured a $9.00M Seed Round investment on 25 April 2024 to advance their groundbreaking research. RevOpsis Therapeutics presents an exciting opportunity for investors seeking to support innovative approaches to complex disease treatment within the Health Care and Life Sciences industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | $9.00M | - | 25 Apr 2024 | |
| Grant | $7.50M | - | 25 Apr 2024 | |
| Venture Round | $7.90M | - | 09 Aug 2023 |
We care about your data, and we'd love to use cookies make your experience better.